Want to join the conversation?
$AMGN said the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study. The study evaluated the efficacy of drug BLINCYTO (blinatumomab) versus standard of care in adult patients with a type of leukemia.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th